This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunology  • Immunologic Disorders  • Transplantation, Other  • Corneal Disorders  • Alert me on articles by topic

Judy I. Ou, MD; Edward E. Manche, MD

Arch Ophthalmol. 2007;125(8):1131-1132.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Conductive keratoplasty (CK) was approved by the US Food and Drug Administration in March 2004 for the correction of hyperopia ranging from +0.75 to +3.00 diopters (D) and 0.75 D or less of cylinder in patients older than 40 years.¹ With CK, hyperopic correction is achieved through the use of a nonablative radiofrequency that shrinks corneal stromal collagen and steepens the central cornea. A keratoplast is used to apply 8 to 32 treatment spots at the 6-, 7-, or 8-mm optical zone.

Patients chosen for CK are carefully screened to avert ocular complications. We report the case of a patient with previously undiagnosed Sjögren syndrome who developed corneal perforation after CK.

Report of a Case

A 52-year-old Chinese woman with uncorrected visual acuity of 20/25 OU and dry eyes with normal meibomian gland status underwent uncomplicated CK of the right eye because of hyperopia (16 spots . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION